Retinal implant for central vision loss in inherited eye disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new implant (PRIMA) placed under the retina to help restore central vision in people with inherited retinal degeneration. If you have very poor central vision and a large enough area of retinal damage, this device may help you see better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a confirmed inherited retinal disease that affects the central vision in both eyes.
- Your vision in the eye to be treated is 20/320 or worse (very poor central vision).
- The damaged area in the center of your retina is at least the size of the implant (about 4.5 mm²).
- You are willing and able to attend all follow-up visits and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This study follows people with inherited retinal diseases to learn how these conditions progress and how genetic changes relate to symptoms. It may help improve future care and treatments.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This study is looking at how people with inherited retinal disease that affects peripheral vision see and move around. It will test a new way to measure vision and navigation to see if it can help doctors understand how the disease affects daily life.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.